Ubs Group Ag Neuro Bo Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.4 - $0.9 $3,274 - $7,368	-8,187 Reduced 72.75%	3,066 $1,000
Q1 2022 May 16, 2022	BUY	$0.72 - $1.54 $8,102 - $17,329	11,253 New	11,253 $10,000
Q4 2021 Feb 14, 2022	SELL	$1.22 - $2.5 $1,265 - $2,592	-1,037 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.73 - $4.52 $5,034 - $8,334	-1,844 Reduced 64.01%	1,037 $4,000
Q2 2021 Aug 13, 2021	BUY	$2.74 - $4.63 $109 - $185	40 Added 1.41%	2,881 $10,000
Q1 2021 May 12, 2021	BUY	$3.93 - $6.68 $7,455 - $12,671	1,897 Added 200.95%	2,841 $13,000
Q4 2020 Feb 11, 2021	SELL	$5.02 - $6.59 $4,864 - $6,385	-969 Reduced 50.65%	944 $5,000
Q3 2020 Nov 12, 2020	BUY	$5.41 - $8.67 $784 - $1,257	145 Added 8.2%	1,913 $11,000
Q2 2020 Jul 31, 2020	BUY	$8.05 - $29.44 $14,232 - $52,049	1,768 New	1,768 $14,000
Q1 2020 May 01, 2020	SELL	$7.24 - $30.0 $5,661 - $23,460	-782 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.83 - $9.9 $5,341 - $7,741	782 New	782 $7,000

Ticker NRBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 888,693
Market Cap $2.4M
Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the tr...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.